256 related articles for article (PubMed ID: 18205228)
1. Genotype dependence of peptide-based immunoassays for the detection of HCV core antibodies.
Muerhoff AS; Gutierrez R; Kyrk C; Leary T; Schlauder G; Dawson G; Desai SM
J Med Virol; 2008 Mar; 80(3):411-8. PubMed ID: 18205228
[TBL] [Abstract][Full Text] [Related]
2. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of core and NS4B synthetic peptide-based immunoassays for the detection of hepatitis C virus antibodies in clinical samples from Cameroon, Central Africa.
Njouom R; Nerrienet E; Budkowska A; Maillard P; Rousset D; Kalinina O; Mavromara P;
J Clin Virol; 2010 Sep; 49(1):61-4. PubMed ID: 20621554
[TBL] [Abstract][Full Text] [Related]
4. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
Bain C; Parroche P; Lavergne JP; Duverger B; Vieux C; Dubois V; Komurian-Pradel F; Trépo C; Gebuhrer L; Paranhos-Baccala G; Penin F; Inchauspé G
J Virol; 2004 Oct; 78(19):10460-9. PubMed ID: 15367612
[TBL] [Abstract][Full Text] [Related]
5. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.
Missale G; Cariani E; Lamonaca V; Ravaggi A; Rossini A; Bertoni R; Houghton M; Matsuura Y; Miyamura T; Fiaccadori F; Ferrari C
Hepatology; 1997 Sep; 26(3):792-7. PubMed ID: 9303515
[TBL] [Abstract][Full Text] [Related]
6. Expression of the full-length HCV core subgenome from HCV gentoype-1a and genotype-3a and evaluation of the antigenicity of translational products.
Ansari MA; Irshad M; Agarwal SK; Chosdol K
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):806-13. PubMed ID: 23442416
[TBL] [Abstract][Full Text] [Related]
7. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan.
Agha S; Tanaka Y; Saudy N; Kurbanov F; Abo-Zeid M; El-Malky M; Khalaf M; Ohta N; Yoshizawa H; Mizokami M
J Med Virol; 2004 Jun; 73(2):216-22. PubMed ID: 15122795
[TBL] [Abstract][Full Text] [Related]
8. Antigenic relevance of F protein in chronic hepatitis C virus infection.
Komurian-Pradel F; Rajoharison A; Berland JL; Khouri V; Perret M; Van Roosmalen M; Pol S; Negro F; Paranhos-Baccalà G
Hepatology; 2004 Oct; 40(4):900-9. PubMed ID: 15382175
[TBL] [Abstract][Full Text] [Related]
9. Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus.
Zhou YH; Moriyama M; Esumi M
Virology; 1999 Apr; 256(2):360-70. PubMed ID: 10191201
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
[TBL] [Abstract][Full Text] [Related]
11. Use of overlapping synthetic peptides to characterize samples from blood donors with indeterminate results to hepatitis C virus core antigen.
León P; López JA; Elola C; Lee SR; Calmann M; Echevarría JM
Vox Sang; 1998; 75(1):32-6. PubMed ID: 9745151
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prevalence of anti-hepatitis C virus antibodies in differing South American populations.
Robinson JW; Rosas M; Guzman F; Patarroyo ME; Moreno A
J Med Virol; 1996 Oct; 50(2):188-92. PubMed ID: 8915886
[TBL] [Abstract][Full Text] [Related]
13. Artificial NS4 mosaic antigen of hepatitis C virus.
Chang JC; Ruedinger B; Cong M; Lambert S; Lopareva E; Purdy M; Holloway BP; Jue DL; Ofenloch B; Fields HA; Khudyakov YE
J Med Virol; 1999 Dec; 59(4):437-50. PubMed ID: 10534724
[TBL] [Abstract][Full Text] [Related]
14. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein.
Cerino A; Boender P; La Monica N; Rosa C; Habets W; Mondelli MU
J Immunol; 1993 Dec; 151(12):7005-15. PubMed ID: 7505020
[TBL] [Abstract][Full Text] [Related]
15. Predominance of antibodies to hepatitis C virus envelope proteins in various disease statuses of hepatitis C.
PodurI CD; Khanna A; Khundmiri SJ; Khaja MN; Kumar KS; Sugunan VS; Habibullah CM; Das MR
Acta Virol; 2001 Feb; 45(1):1-6. PubMed ID: 11394572
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to a novel antigen in acute hepatitis C virus infections.
Tobler LH; Stramer SL; Chien DY; Lin S; Arcangel P; Phelps BH; Cooper SL; Busch MP
Vox Sang; 2007 Jan; 92(1):1-7. PubMed ID: 17181584
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the antibody reactivity to synthetic peptides from different parts of the hepatitis C virus genome.
Pujol FH; Khudyakov YE; Devesa M; León G; Blitz-Dorfman L; Monsalve F; Lambert SB; Kalinina TY; Liprandi F; Fields HA
Viral Immunol; 1996; 9(2):89-96. PubMed ID: 8822625
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of a panel of monoclonal antibodies raised against recombinant HCV core protein.
Ferns RB; Tuke PW; Sweenie CH
J Med Virol; 1996 Nov; 50(3):221-9. PubMed ID: 8923286
[TBL] [Abstract][Full Text] [Related]
19. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
